论文部分内容阅读
对３３例植入心房电极者进行起搏阈值的随访，结果表明：起搏阈值峰值为１．４４±０．７４Ｖ／０．５ｍｓ，出现在植入后两周内；慢性期起搏阈值为１．２２±０．４０Ｖ／０．５ｍｓ；伴器质性心脏病患者慢性期起搏阈值（１．７０士０．３７Ｖ／０．５ｍｓ）明显高于不伴器质性心脏病者（１．１６±０．３７Ｖ／０．５ｍｓ），Ｐ＜０．０１；激素电极的起搏阈值峰值（１．１２±０．２９Ｖ／０．５ｍｓ）和慢性期起搏阈值（０．７７±０．１７Ｖ／０．５ｍｓ）均显著低于非激素电极（１．８０±０．６８Ｖ／０．５ｍｓ和１．４０±０．３３Ｖ／０．５ｍｓ），Ｐ＜０．０５及０．００１。提出在非特殊情况下，将出厂时的电能由５．０Ｖ／０．５ｍｓ降至２．５Ｖ／０．５ｍｓ既可保证有效起搏，又可节省电能，从而延长起搏器的使用寿命。
Thirty-three patients with atrial electrodes were followed up for pacing threshold. The results showed that the peak value of pacing threshold was 1.44 ± 0.74V / 0.5ms and appeared within two weeks after implantation. The pacing threshold of chronic phase was 1.22 ± 0.40V / 0.5ms; chronic pacing threshold (1.70 ± 0.37V / 0.5ms) in patients with organic heart disease was significantly higher than those without organic heart disease .16 ± 0.37V / 0.5ms), P <0.01; the peak values of pacing threshold (1.12 ± 0.29V / 0.5ms) and the chronic pacing threshold (0.77 ± 0 .17V / 0.5ms) were significantly lower than the non-hormonal electrodes (1.80 ± 0.68V / 0.5ms and 1.40 ± 0.33V / 0.5ms), P <0.05 and 0.001. It is proposed that in non-special cases, the power delivered from the factory can be reduced from 5.0V / 0.5ms to 2.5V / 0.5ms to ensure effective pacing and save energy, thus prolonging the service life of the pacemaker.